FDA Intensifies Crackdown: 30 Warning Letters Target Telehealth Firms Over Compounded GLP-1 Drugs

The U.S. Food and Drug Administration (FDA) is escalating its enforcement campaign against the compounding of GLP-1 receptor agonist drugs, such as semaglutide and tirzepatide, which are widely used for weight loss and diabetes. In a significant move, the agency has issued a fresh batch of 30 warning letters to telehealth companies marketing compounded versions of these medications. The letters target firms that are allegedly producing and distributing these drugs without proper regulatory oversight, raising serious concerns about patient safety, drug purity, and sterility. The FDA's action highlights a growing regulatory battle in the lucrative weight-loss drug market, where demand has far outstripped the supply of FDA-approved brand-name products like Wegovy, Ozempic, and Mounjaro. This shortage has created a gray market where compounding pharmacies and telehealth platforms offer purportedly similar formulations. The agency warns that compounded drugs have not undergone the rigorous safety, efficacy, and quality reviews required for FDA approval, posing potential risks to consumers. This crackdown signals the FDA's intent to clamp down on what it views as unauthorized and potentially unsafe manufacturing practices within the booming telehealth and compounding sectors.